Barth 1981.

Methods	Double blinded: yes.
Participants	N=215 European men with symptomatic BPH, age > 50. Lost to follow‐up: 67 (31%).
Interventions	Control 1: placebo (n=46). Treatment 2: P. africanum extract (Docosanol) 100 mg daily (n=50). Control 2: Sitosterin 30 mg (n=34). Treatment 2: P. africanum extract (Docosanol) 100 mg daily (n=37). Control 3: ERU* 300 mg (n=24). Treatment 3: P. africanum extract (Docosanol) 100 mg daily (n=24). Treatment duration: 8 weeks.
Outcomes	Nocturia; peak urine flow; residual volume. Adverse events.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear